SELLAS Life Sciences Group, Inc. Total Long-Term Debt
SELLAS Life Sciences Group, Inc. (SLS) had Total Long-Term Debt of $100.00 thousand as of 2018-09-30, per its 10-Q filed 2018-11-14.
Discontinued › Balance Sheet › Liabilities › Long-Term Debt, Unclassified
us-gaap:LongTermDebt · last filed 2018-11-14
- 2018-09-30: Long-term Debt $100.00K.
- 2018-06-30: Long-term Debt $7.80M.
- 2018-03-31: Long-term Debt $9.70M.
- 2017-12-31: Long-term Debt $10.99M.
| Period end | Long-term Debt |
|---|---|
| 2018-09-30 | $100.00K 10-Q · filed 2018-11-14 |
| 2018-06-30 | $7.80M 10-Q · filed 2018-08-14 |
| 2018-03-31 | $9.70M 10-Q · filed 2018-05-15 |
| 2017-12-31 | $10.99M 10-K · filed 2018-04-13 |
| 2014-12-31 | $8.16M 8-K · filed 2015-12-04 |
| 2013-12-31 | $10.00M 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |